Bristol-Myers Squibb

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015 01:50 PM

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

More... »

Quest Diagnostics

Safe-Biopharma launches cyber security consulting service for life science, healthcare

Friday, April 24, 2015 01:18 PM

SAFE-BioPharma Association has created SBP Digital Trust Consulting, a resource of internationally recognized identity and access management (IAM) policy and technical experts for life science and healthcare companies seeking to develop improved cyber security strategies.

More... »


Incyte joins Safe-Biopharma Association

Friday, April 17, 2015 12:39 PM

Incyte, a Delaware-based biopharmaceutical company, has joined SAFE-BioPharma Association, a nonprofit industry coalition responsible for the ongoing development and implementation of the SAFE-BioPharma digital identity and signature standard.

More... »

Bristol-Myers Squibb, uniQure collaborate on gene therapies for cardiovascular diseases

Wednesday, April 8, 2015 01:03 PM

Bristol-Myers Squibb has inked an agreement with uniQure, a gene therapy developer based in the Netherlands, for exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases.

More... »

FDA expands approved use of Opdivo to treat lung cancer

Thursday, March 5, 2015 01:42 PM

The FDA has expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

More... »

Bristol-Myers Squibb, Bavarian Nordic ink agreement for PROSTVAC

Wednesday, March 4, 2015 01:06 PM

Bristol-Myers Squibb has signed an exclusive option to license and commercialize PROSTVAC, Bavarian Nordic's investigational phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

More... »

Bristol-Myers Squibb to acquire Flexus Biosciences

Monday, February 23, 2015 01:02 PM

Bristol-Myers Squibb has signed a definitive agreement to acquire all of the outstanding capital stock of Flexus Biosciences, a San Carlos, Calif.-based, privately held biotech focused on the discovery and development of novel anti-cancer therapeutics. The transaction has a potential total consideration of $1.25 billion, including $800 million upfront and development milestones that, upon achievement, could total up to $450 million. The transaction has been approved by the boards of directors of both companies and by the stockholders of Flexus.

More... »

Rigel, Bristol-Myers Squibb ink R&D collaboration

Monday, February 23, 2015 01:01 PM

Rigel Pharmaceuticals and Bristol-Myers Squibb have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors. T

More... »

FDA approves record 41 new drugs in 2014, over 40% for rare diseases

Friday, January 16, 2015 02:52 PM

Pharmaceutical innovation had a banner year in 2014, as the FDA approved 41 novel drugs and biologics—the largest number in 18 years and a 52% increase from the 27 approved in 2013.

More... »

Eli Lilly inks agreements with Merck, Bristol-Myers Squibb

Wednesday, January 14, 2015 12:21 PM

Eli Lilly has formed two separate collaboration agreements. The first agreement with Merck is an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials. The second, with Bristol-Myers Squibb, is a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of BMS' immunotherapy Opdivo (nivolumab) in combination with Lilly's galunisertib (LY2157299).

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs